← back to dashboard

ESPR

Esperion Therapeutics, Inc.
Composite
0.99
EDGAR
0.99
Filings (90d)
4
Peak
0.97
Last Signal
2026-07-13T09:10

All Filings

Filed Form Items Signal Score Summary Link
2026-07-13 09:10 8-K ["1.01", "1.02"] merger agreement 1.00 Merger between Esperion and Essence Parent consummated July 13, 2026; Esperion is now wholly owned subsidiary. SEC · detail
2026-07-08 08:32 8-K ["5.07"] merger agreement 0.98 Stockholders approved merger agreement with Essence Parent Inc.; MergerCo to merge with Esperion as surviving subsidiary. SEC · detail
2026-06-18 16:04 8-K ["9.01"] merger agreement 1.00 Esperion completed acquisition of Corstasis per merger agreement dated March 2, 2026. SEC · detail
2026-06-16 16:00 8-K ["8.01"] merger agreement 0.98 Esperion merger with ArchiMed affiliate approved by HSR; stockholder vote scheduled July 8, 2026. SEC · detail
2026-06-09 16:01 8-K ["8.01"] merger agreement 0.98 Esperion merger with ArchiMed affiliate cleared by German antitrust; stockholder vote scheduled July 8, 2026. SEC · detail
2026-06-08 06:02 DEFM14A merger agreement 0.99 Definitive proxy statement for completed merger agreement: Esperion acquired by ArchiMed affiliate for $3.16/share + contingent payments. SEC · detail
2026-06-01 16:22 8-K ["5.02", "5.07", "9.01"] other 0.05 Routine annual meeting results; no M&A signals detected. SEC · detail
2026-05-29 17:17 PREM14A merger agreement 0.98 Esperion entering definitive merger with ArchiMed affiliate at $3.16/share plus contingent payments. SEC · detail
2026-05-01 07:55 8-K ["1.01"] merger agreement 0.98 Esperion entered definitive merger agreement with Essence Parent Inc.; $3.16/share cash plus CVR with up to $100M contingent payments. SEC · detail